David A. Ramsay

Mr. Ramsay has served as a member of Savara’s Board of Directors since April 2017 and served as a member of the Board of Directors of Mast Therapeutics, Inc. (Savara closed a reverse merger with Mast Therapeutics in April 2017). Mr. Ramsay currently provides consulting services to publicly traded and privately held biotechnology companies and serves on the Board of Directors of La Jolla Pharmaceutical Company and the privately held company Exuma Biotech, Inc. Previously, Mr. Ramsay served as Senior Vice Pesident and Chief Financial Officer of Bonti, Inc., a private, clinical-stage biotechnology company focused on the development and commercialization of neurotoxin products for therapeutic and aesthetic applications. Prior to that, he was Chief Financial Officer of Halozyme Therapeutics, Inc., a biotechnology company developing and commercializing novel oncology therapies. Mr. Ramsay also served as Halozyme’s Vice President, Corporate Development. Before Halozyme, Mr. Ramsay served as Vice President, Chief Financial Officer of Lathian Systems, Inc., a provider of technology-based sales solutions for the life sciences industry, and as Vice President, Treasurer and Director, Corporate Finance with Valeant Pharmaceuticals International, Inc. (formerly ICN Pharmaceuticals, Inc.), a multinational specialty pharmaceutical company. Mr. Ramsay began his career at Deloitte & Touche, where he obtained his CPA license. He holds a B.S. in Business Administration from the University of California, Berkeley, and an M.B.A. with a dual major in finance and strategic management from The Wharton School at the University of Pennsylvania.